Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Cells for Refractory CD19+ B Cell Lymphoma
NCT02992834Phase 4Unknown
- Start
- Dec 2016
- Primary completion
- Aug 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 4 trial of CD19 CAR-T-cells in B cell lymphoma. Status: unknown.
02
Drugs
CD19 CAR-T-cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02992834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992834.